Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Tumor-Agnostic 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

Cyclophosphamide 641Bevacizumab 552Paclitaxel 534Carboplatin 533Cisplatin 480pembrolizumab 456Gemcitabine 422Docetaxel 415Rituximab 386Radiotherapy 373Dexamethasone 351Doxorubicin 330Nivolumab 308Fluorouracil 286Capecitabine 260Etoposide 245Prednisone 244Oxaliplatin 242Erlotinib Hydrochloride 242Cytarabine 233Lenalidomide 232Trastuzumab 226Pemetrexed 220Vincristine 212fludarabine phosphate 208Leucovorin 208Cetuximab 208Filgrastim 204Bortezomib 193Methotrexate 183

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Has results × eryaspase × Clear all
NCT03267030 2024-03-15

Asparaginase Encapsulated in Erythrocytes for Patients With ALL and Hypersensitivity to PEG-asparaginase

Aarhus University Hospital

Phase 2 Completed
55 enrolled 9 charts
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03665441 2022-10-18

Trybeca-1

ERYtech Pharma

Phase 3 Completed
512 enrolled 19 charts
Tumor-Agnostic

Neoplasms

NCT01810705 2022-02-21

ENFORCE

ERYtech Pharma

Phase 2 Completed
123 enrolled 8 charts
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡